' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a.
Hartl, A; Hochreiter, R; Stepanoska, T; Ferreira, F; Thalhamer, J;
Allergy. 2004; 59(1):65-73
Originalarbeiten (Zeitschrift)


Hartl Arnulf Josef


An estimated 100 million individuals suffer from birch pollen allergy. More than 95% of birch pollen-allergic subjects react with the major birch pollen allergen Bet v 1a, and almost 60% of them are sensitized exclusively to this allergen.
DNA immunization using the Bet v 1a gene was evaluated with respect to its prophylactic and therapeutic efficacy.
A DNA vaccine containing the entire Bet v 1a cDNA under the control of a CMV-promoter was constructed. In order to estimate the protective efficiency, animals received three injections of this vaccine prior to sensitization with recombinant Bet v 1a. Vice versa, in a therapeutic approach, sensitization was followed by treatment with the DNA vaccine.
The Bet v 1a DNA vaccine induced strong Bet v 1-specific antibody responses with a Th1-biased response type. Animals which received the DNA vaccine were protected against a following allergic sensitization with Bet v 1a. The protective effect was characterized by suppression of Bet v 1-specific immunoglobulin (Ig)E production, lack of basophil activation and enhanced interferon (IFN)-gamma expression. In a therapeutic situation, treatment of sensitized animals with DNA vaccines decreased IgE production, IgE-mediated basophil release and drastically reduced anaphylactic activity as measured by passive cutaneous anaphylaxis assays. Concerning the cellular immune response, DNA immunization induced a sustaining and dominant shift from a Th2 type response towards a balanced Th1/Th2 type response as indicated by increased IFN-gamma but unchanged IL-5 levels in lymphoproliferation assays.
The results demonstrate the allergen-specific protective and therapeutic efficacy of a DNA vaccine encoding the clinically highly relevant allergen Bet v 1a indicating the suitability of this concept for the treatment of allergic diseases.

Useful keywords (using NLM MeSH Indexing)

Allergens/adverse effects




Desensitization, Immunologic/methods*

Disease Models, Animal




Immunity, Cellular/physiology

Immunoglobulin G/analysis


Mice, Inbred BALB C

Pollen/adverse effects



Random Allocation

Reference Values

Sensitivity and Specificity

Statistics, Nonparametric


Vaccines, DNA/pharmacology*

Find related publications in this database (Keywords)

Bet v 1a
DNA vaccines
gene vaccines
Th1/Th2 cells